Evidence map›Paper›PMID 40806481›Full record

ReviewInternational journal of molecular sciences2025

Combination Therapy Using Phytochemicals and PARP Inhibitors in Hybrid Nanocarriers: An Optimistic Approach for the Management of Colon Cancer.

Mohammad Javed Qureshi, Gurpreet Kaur Narde, Alka Ahuja, Dhanalekshmi Unnikrishnan Meenakshi, Khalid Al Balushi

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in International journal of molecular sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Mohammad Javed QureshiDepartment of Pharmaceutics, College of Pharmacy, National University of Science and Technology, P.O. Box 620, Muscat PC130, Oman.
Gurpreet Kaur NardeDepartment of Pharmaceutics, College of Pharmacy, National University of Science and Technology, P.O. Box 620, Muscat PC130, Oman.ORCID 0000-0001-5182-4622
Alka AhujaDepartment of Pharmaceutics, College of Pharmacy, National University of Science and Technology, P.O. Box 620, Muscat PC130, Oman.ORCID 0000-0002-9295-2521
Dhanalekshmi Unnikrishnan MeenakshiDepartment of Pharmacology and Biological Sciences, College of Pharmacy, National University of Science and Technology, P.O. Box 620, Muscat PC130, Oman.ORCID 0000-0002-2689-4079
Khalid Al BalushiDepartment of Pharmaceutics, College of Pharmacy, National University of Science and Technology, P.O. Box 620, Muscat PC130, Oman.ORCID 0000-0003-4638-8787

Funding

Ministry of Higer Education Research and Innovation (MoHERI) BFP/RGP/HSS/23/397
6 · The paper itself

Abstract

DNA damage repair is a hallmark of any cancer growth, eventually leading to drug resistance and death. The poly ADP-ribose polymerase (PARP) enzyme is vital in repairing damaged DNA in normal and cancer cells with mutated

Indexed as

Antineoplastic Combined Chemotherapy ProtocolsColonic NeoplasmsDrug CarriersNanoparticlesPhytochemicalsPoly(ADP-ribose) Polymerase InhibitorsAnimalsHumansPhthalazinesPiperazinesDrug CarriersolaparibPhthalazinesPhytochemicalsPiperazinesPoly(ADP-ribose) Polymerase Inhibitorscombination therapylipid hybrid nanoparticlesOlaparibPARP inhibitorphytochemicals

Identifiers

PMID40806481
PMCPMC12347401

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.